Latest Headlines

  1. Bora Pharmaceuticals And Corealis Pharma Forge Strategic Alliance To Deliver Seamless, End-To-End Oral Solid Dose Development 12/9/2025

    Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a global leader in pharmaceutical manufacturing, and Corealis Pharma Inc., a leading early-phase Contract Development Manufacturing Organization (CDMO), have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and manufacturing. The collaboration will simplify the drug development process and provide a more scalable pathway to commercialization via a single continuum.

  2. Marchesini Group And AST Unite To Expand Global Sterile Fill-Finish Capabilities 12/9/2025

    Marchesini Group, a leader in pharmaceutical packaging machinery, and AST, a U.S leader in the drug product manufacturing industry, have entered a strategic partnership that combines the expertise, technologies, and global reach of two highly respected industry leaders.

  3. Late-Model Lab & Bioprocess Equipment From Premier Biopharma Facility To Be Offered For Sale December 4–9, 2025 12/8/2025
  4. AsymBio Commences Commercial Operations At Fengxian Base 12/8/2025

    Shanghai, AsymBio, a technology-driven global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), today announced the official start of commercial production at its Shanghai Fengxian Commercial Manufacturing Base.

  5. Bora Pharmaceuticals Marks Five Years In Mississauga, Canada, Strengthening Its Commitment To Onshore And Global CDMO Excellence 12/5/2025

    Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today celebrates the five-year anniversary of its Mississauga, Ontario, Canada facility, a key hub in the company’s North American operations and a cornerstone of its expanding international CDMO network. The milestone will be celebrated onsite with employees, partners, and community stakeholders.

  6. Techceuticals Announces 2026 Solid Dosage Manufacturing Process Training Schedule 12/5/2025

    echceuticals, a leading authority in pharmaceutical manufacturing education, is pleased to announce its 2026 Solid Dosage Manufacturing Process Training series—three opportunities for professionals to gain practical, hands-on instruction in tablet and capsule production. Each session is designed to equip attendees with the skills and process knowledge needed to develop, manufacture, and troubleshoot solid oral dosage forms with confidence.

  7. Quotient Sciences And Intrepid Labs Form Strategic Partnership To Accelerate AI-Guided Formulation Development 12/4/2025

    Under the new agreement, Quotient Sciences will have access to Intrepid’s machine learning model, ANDROMEDA, the first AI platform to develop and optimize clinical performance of drug products. The platform is designed to significantly reduce formulation development timelines, reduce API demands and increase formulation understanding, helping clients reach critical milestones faster and improve confidence in clinical success.

  8. Large-Capacity Double Planetary Mixer Ideal For Highly Viscous Materials 11/26/2025

    ROSS recently completed the largest Double Planetary Mixer in its US history, a Model DPM-750 capable of mixing up to an impressive 750 gallons per batch and engineered with safety features for a Class I, Division 1, Group D hazardous environment. This heavy-duty mixer delivers the robust agitation required for ultra-high viscosity materials while adhering to demanding safety standards.

  9. CSL To Build Out U.S. Plasma Capabilities Through $1.5B Investment 11/24/2025

    Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced plans to expand its U.S. presence over the next five years, resulting in approximately US$1.5b in U.S. capital investments. These investments will generate hundreds of high-quality American jobs, strengthen U.S. manufacturing capabilities of plasma-derived therapies (PDTs), and help secure the U.S. medicine supply chain.  This reflects CSL’s commitment to meet the growing clinical need for immunoglobulin (Ig) over the long term.

  10. Equipment Auction Announced For Sutro Biopharma Assets 11/24/2025

    December 15-16, 2025: Featuring late-model lab, R&D and manufacturing equipment surplus to future needs of Sutro BioPharma: spray dryer, chromatography systems, Westfalia seperators, HPLC’s & more.